CP19
CP19, a histamine receptor antagonist, is an entry inhibitor against both Ebolavirus (EBOV) and Marburgvirus (MARV) with IC50s of 3.4 μM and 29.5 μM, respectively. CP19 has SI values of 29.4 and 3.4 for EBOV and MARV, respectively. CP19 has antiviral activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1018148-68-9
- Fòrmula: C26H30N2O5
- Peso molecular:450.53
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Histamine Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
EBOV |
MARV |
Histamine Receptor |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | CC50 |
>100 μM
Compound: 1; CP19
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by Celltiter-Glo assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by Celltiter-Glo assay
|
[PMID: 32707357] |
Chemical Information
-
No. CAS 1018148-68-9
-
Peso molecular 450.53
-
Fòrmula C26H30N2O5
-
SMILES
O=C1OC2=C(C(C)=C1CC3=CC=CC=C3)C=CC(OCC(CN4CCC(CC4)C(N)=O)O)=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CP19 Related Classifications
HY-146815 Related Classifications
Powered by Bioz